Inferring infection hazard in wildlife populations by linking data across individual and population scales. (16th January 2017)

• Record Type: Journal Article
• Authors: Pepin, Kim M.; Kay, Shannon L.; Golas, Ben D.; Shriner, Susan S.; Gilbert, Amy T.; Miller, Ryan S.; Graham, Andrea L.; Riley, Steven; Cross, Paul C.; Samuel, Michael D.; Hooten, Mevin B.; Hoeting, Jennifer A.; Lloyd‐Smith, James O.; Webb, Colleen T.; Buhnerkempe, Michael G.
• Editors: Aubry, Lise
• Is Part Of: Ecology letters. Volume 20:Number 3(2017)
• Page Start: 275
• Page End: 292
• Publication Date: 2017-01-16
• Subjects: Antibody -- antibody kinetics -- disease hazard -- force of infection -- incidence -- individual‐level variation -- influenza -- serosurveillance -- transmission -- within‐host; Ecology -- Periodicals; 577
• DOI: 10.1111/ele.12732
• Languages: English
• ISSNs: 1461-023X

Abstract

Abstract: Our ability to infer unobservable disease‐dynamic processes such as force of infection (infection hazard for susceptible hosts) has transformed our understanding of disease transmission mechanisms and capacity to predict disease dynamics. Conventional methods for inferring FOI estimate a time‐averaged value and are based on population‐level processes. Because many pathogens exhibit epidemic cycling and FOI is the result of processes acting across the scales of individuals and populations, a flexible framework that extends to epidemic dynamics and links within‐host processes to FOI is needed. Specifically, within‐host antibody kinetics in wildlife hosts can be short‐lived and produce patterns that are repeatable across individuals, suggesting individual‐level antibody concentrations could be used to infer time since infection and hence FOI. Using simulations and case studies (influenza A in lesser snow geese and Yersinia pestis in coyotes), we argue that with careful experimental and surveillance design, the population‐level FOI signal can be recovered from individual‐level antibody kinetics, despite substantial individual‐level variation. In addition to improving inference, the cross‐scale quantitative antibody approach we describe can reveal insights into drivers of individual‐based variation in disease response, and the role of poorly understood processes such as secondary infections, in population‐level dynamics of disease.